These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12972709)

  • 1. Targeting genetically modified macrophages to the glomerulus.
    Wilson HM; Kluth DC
    Nephron Exp Nephrol; 2003; 94(4):e113-8. PubMed ID: 12972709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene transfer into inflamed glomeruli using macrophages transfected with adenovirus.
    Kluth DC; Erwig LP; Pearce WP; Rees AJ
    Gene Ther; 2000 Feb; 7(3):263-70. PubMed ID: 10694804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets.
    Burke B; Sumner S; Maitland N; Lewis CE
    J Leukoc Biol; 2002 Sep; 72(3):417-28. PubMed ID: 12223508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis.
    Kluth DC; Ainslie CV; Pearce WP; Finlay S; Clarke D; Anegon I; Rees AJ
    J Immunol; 2001 Apr; 166(7):4728-36. PubMed ID: 11254734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage activation and programming and its role for macrophage function in glomerular inflammation.
    Erwig LP; Rees AJ
    Kidney Blood Press Res; 1999; 22(1-2):21-5. PubMed ID: 10352404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of antibody-induced acute glomerulonephritis with genetically modified bone marrow-derived vehicle cells.
    Yokoo T; Ohashi T; Utsunomiya Y; Kojima H; Imasawa T; Kogure T; Hisada Y; Okabe M; Eto Y; Kawamura T; Hosoya T
    Hum Gene Ther; 1999 Nov; 10(16):2673-8. PubMed ID: 10566895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal transfer of genetically engineered cells.
    Kitamura M
    J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S154-8. PubMed ID: 11065349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfer of genetically engineered macrophages into the glomerulus.
    Kitamura M; Sütö TS
    Kidney Int; 1997 Apr; 51(4):1274-9. PubMed ID: 9083297
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene therapy targeting kidney diseases: routes and vehicles.
    Isaka Y
    Clin Exp Nephrol; 2006 Dec; 10(4):229-35. PubMed ID: 17186326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfer of genetically engineered cells to the glomerulus.
    Kitamura M
    Exp Nephrol; 1999; 7(3):259-66. PubMed ID: 10352367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiinflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis. The modulation of macrophage migration and eicosanoid metabolism.
    Schreiner GF; Rovin B; Lefkowith JB
    J Immunol; 1989 Nov; 143(10):3192-9. PubMed ID: 2809195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of genetically modified macrophages elucidated TGF-beta-mediated 'self-defence' of the glomerulus against local action of macrophages.
    Kitamura M
    Nephrol Dial Transplant; 1999; 14 Suppl 1():35-8. PubMed ID: 10048446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis.
    Lan HY; Mu W; Yang N; Meinhardt A; Nikolic-Paterson DJ; Ng YY; Bacher M; Atkins RC; Bucala R
    Am J Pathol; 1996 Oct; 149(4):1119-27. PubMed ID: 8863661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage-induced glomerular fibrin deposition in experimental glomerulonephritis in the rabbit.
    Holdsworth SR; Tipping PG
    J Clin Invest; 1985 Oct; 76(4):1367-74. PubMed ID: 4056035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of macrophage activation in anti-Thy-1.1 nephritis.
    Minto AW; Erwig LP; Rees AJ
    Am J Pathol; 2003 Nov; 163(5):2033-41. PubMed ID: 14578202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo transfer of engineered macrophages into the glomerulus: endogenous TGF-beta-mediated defense against macrophage-induced glomerular cell activation.
    Sütö TS; Fine LG; Shimizu F; Kitamura M
    J Immunol; 1997 Sep; 159(5):2476-83. PubMed ID: 9278341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene delivery using human cord blood-derived CD34+cells into inflamed glomeruli in NOD/SCID mice.
    Yokoo T; Ohashi T; Utsunomiya Y; Okamoto A; Suzuki T; Shen JS; Tanaka T; Kawamura T; Hosoya T
    Kidney Int; 2003 Jul; 64(1):102-9. PubMed ID: 12787400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune therapy with macrophages: present status and critical requirements for implementation.
    Bartoleyns J; Romet-Lemonne JL; Chokri M; Lopez M
    Immunobiology; 1996 Oct; 195(4-5):550-62. PubMed ID: 8933156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical usefulness of CD68 staining in children with various glomerular diseases].
    Maekawa K; Shibano T; Sawaki J; Mae H; Hattori M; Tanizawa T
    Nihon Jinzo Gakkai Shi; 2014; 56(4):532-7. PubMed ID: 24956886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glomerular expression of macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in patients with various forms of glomerulonephritis.
    Matsuda M; Shikata K; Makino H; Sugimoto H; Ota Z
    Lab Invest; 1996 Sep; 75(3):403-12. PubMed ID: 8804363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.